COVID‑19 Antiviral & Monoclonal Antibody High‑Yield Guide for Gulf Prometric Exams (DHA, SMLE, HAAD, MOH)

Why Master COVID‑19 Antiviral & Monoclonal Antibody Therapy?

Since 2020, the COVID‑19 pandemic has reshaped clinical practice worldwide. In the Gulf Cooperation Council (GCC) countries, licensing exams such as the DHA, SMLE, HAAD, and MOH now test candidates on the latest therapeutic options, including oral antivirals and monoclonal antibodies (mAbs). Understanding drug mechanisms, indications, dosing, and exam‑style pitfalls is essential for a high‑yield pass.

Learning Objectives

• Identify the FDA‑ and EMA‑approved antivirals for SARS‑CoV‑2 infection.
• Describe the spectrum of activity and current variant‑specific recommendations for monoclonal antibodies.
• Apply dosing, contraindications, and drug‑interaction knowledge to clinical vignettes.
• Utilize Study Prometric resources (AI clinical cases, MCQ bank, flashcards, video lectures) to reinforce retention.

Pathophysiology Quick Review

The SARS‑CoV‑2 virus enters host cells via the ACE2 receptor, using its spike (S) protein. Replication relies on the viral RNA‑dependent RNA polymerase (RdRp) and the main protease (M^pro). Therapeutic agents target either viral entry (mAbs) or intracellular replication (antivirals). Remember that the timing of therapy matters: most agents are most effective when given within 5‑7 days of symptom onset.

Oral Antivirals – High‑Yield Facts

1. Nirmatrelvir/Ritonavir (Paxlovid)

• Mechanism: Nirmatrelvir inhibits M^pro; ritonavir boosts its plasma concentration.
• Indication: Non‑hospitalized adults with mild‑moderate COVID‑19 at high risk for progression.
• Dosing: 300 mg nirmatrelvir + 100 mg ritonavir BID for 5 days (adjust for eGFR < 30 ml/min).
• Key contraindications: Severe hepatic impairment, concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin).
• Common adverse effects: Dysgeusia, diarrhea, hypertension.

2. Molnupiravir (Lagevrio)

• Mechanism: Introduces errors into viral RNA via RdRp, leading to error catastrophe.
• Indication: Adults with mild‑moderate disease who cannot take Paxlovid or have drug‑interaction concerns.
• Dosing: 800 mg PO BID for 5 days.
• Contraindications: Pregnancy, lactation, and patients < 18 years.
• Adverse effects: Nausea, dizziness; mutagenic potential is theoretical – avoid in reproductive‑age patients.

3. Remdesivir (Veklury)

• Mechanism: Adenosine analogue that terminates viral RNA synthesis.
• Indication: Hospitalized patients requiring supplemental oxygen but not on invasive ventilation.
• Dosing: 200 mg IV on day 1, then 100 mg IV daily for up to 5 days (extend to 10 days in immunocompromised).
• Monitoring: Liver function (ALT/AST) and renal function (eGFR > 30 ml/min).
• Adverse effects: Infusion‑related reactions, hepatotoxicity, nephrotoxicity.

Monoclonal Antibodies – Variant‑Specific High Yield

mAbs neutralize the virus by binding the spike protein. Because spike mutations differ among variants, the efficacy of each mAb changes over time. Gulf licensing exams now ask candidates to match the appropriate mAb to the circulating variant.

1. Sotrovimab

• Target: Conserved epitope on the S‑protein; retains activity against Omicron BA.1.
• Dosing: 500 mg IV single infusion.
• Current status (2026): Limited efficacy against BA.2‑5; use only when local epidemiology shows BA.1 dominance.

2. Bebtelovimab

• Target: Binds a region unchanged in most Omicron sub‑variants (BA.2‑5, XBB).
• Dosing: 175 mg IV single infusion.
• Key point: Only FDA‑authorized mAb with activity against XBB.1.5 – a common Gulf strain in 2025‑2026.

3. Casirivimab/Imdevimab (REGEN‑COV)

• Mechanism: Dual‑antibody cocktail targeting non‑overlapping epitopes.
• Current relevance: Not recommended for Omicron‑dominant periods; may appear in older exam questions referencing pre‑2022 data.

Choosing the Right Therapy – Exam‑Style Decision Tree

1. Assess patient setting: outpatient vs inpatient.
2. Determine time since symptom onset (≤5 days for oral antivirals, ≤7 days for mAbs).
3. Identify risk factors for progression (age > 65, immunosuppression, uncontrolled diabetes, etc.).
4. Check renal/hepatic function and drug‑interaction profile.
5. Review regional variant data (e.g., XBB.1.5 prevalence → prefer Bebtelovimab).
6. Select the highest‑evidence therapy that fits the above criteria.

In MCQs, the correct answer often follows this logical flow. Memorize the decision algorithm – it’s a classic “high‑yield” exam hook.

Clinical Pearls for the DHA/SMLE/HAAD/MOH Exams

• Timing is king. Any antiviral given > 7 days after symptom onset is unlikely to be correct.
• Drug interactions with Paxlovid are a frequent distractor – remember the strong CYP3A4 inducers.
• Pregnancy contraindication applies only to Molnupiravir; Paxlovid can be used with caution if benefits outweigh risks.
• Renal dose adjustment for Paxlovid (eGFR 30‑60 ml/min → 150 mg nirmatrelvir + 100 mg ritonavir BID).
• Variant awareness – XBB.1.5 → Bebtelovimab; BA.1 → Sotrovimab; BA.2‑5 → Bebtelovimab (if available).

How Study Prometric Accelerates Your Mastery

Study Prometric offers a suite of tools perfectly aligned with this high‑yield topic:

• AI‑Powered Clinical Cases: Simulated outpatient COVID‑19 scenarios that force you to choose the right antiviral or mAb based on timing, comorbidities, and variant data.
• Targeted MCQ Bank: Over 150 curated questions on COVID‑19 therapeutics, each with detailed explanations and references to Gulf guidelines.
• Flashcards & Spaced‑Repetition: Bite‑size cards covering dosing, contraindications, and variant‑specific recommendations – ideal for quick recall before the exam.
• Video Lectures: 10‑minute high‑yield videos that walk through the decision tree, highlighting common exam traps.
• Performance Analytics: Track your accuracy on COVID‑19 therapeutic questions and focus on weak areas before the test day.

Integrating these resources into a 2‑week focused study block will dramatically increase your confidence and score.

Sample 2‑Week Study Schedule

Day	Activity
Day 1‑2	Watch video lecture + read concise guideline summary (1500 words).
Day 3‑4	Complete 30 AI clinical cases; review explanations.
Day 5	Flashcard review (dosing & contraindications) – spaced repetition.
Day 6‑7	Answer 40 MCQs (mixed difficulty); flag incorrect items.
Day 8	Re‑watch key video segments; focus on variant‑specific mAbs.
Day 9‑10	Second round of AI cases – now with time pressure.
Day 11	Flashcard blitz – all cards in one session.
Day 12‑13	Full‑length practice exam (30 COVID‑19 questions + 70 mixed).
Day 14	Review analytics; revisit weakest topics; final flashcard run.

Common Pitfalls & How to Avoid Them

• Mix‑up of dosing intervals: Remember Paxlovid is BID, not QD.
• Assuming all mAbs work against Omicron: Only Bebtelovimab retains activity against XBB sub‑variants.
• Neglecting renal adjustment for Paxlovid: eGFR < 30 ml/min = hold medication.
• Over‑reliance on “any antiviral” answer: Exam writers test specific knowledge; choose the agent that matches the clinical vignette’s constraints.

Final Take‑Home Messages

1. Timing, risk stratification, and variant awareness dictate therapy selection.
2. Memorize the concise dosing tables – they appear verbatim in many MCQs.
3. Use Study Prometric’s AI cases and flashcards to cement decision‑making pathways.
4. Practice with exam‑style questions daily; review explanations to close knowledge gaps.
5. Stay updated on regional variant reports – Gulf health ministries release weekly bulletins that influence exam content.

By integrating these strategies, you’ll turn a complex, evolving therapeutic area into a high‑yield, exam‑ready strength.